Scientific publications

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

Dec 4, 2021 | Magazine: Cancer Cell International

Javier Escudero #  1 , Victoria Heredia-Soto #  1   2 , Yinyin Wang  3 , Patricia Ruiz  4 , Yingying Hu  3 , Alejandro Gallego  5 , Jose Juan Pozo-Kreilinger  4   6 , Virginia Martinez-Marin  5 , Alberto Berjon  4   6 , Eduardo Ortiz-Cruz  7 , Daniel Bernabeu  8 , Jaime Feliu  1   2   5   9 , Jing Tang  3 , Andres Redondo  10   11   12 , Marta Mendiola  13   14

Background: Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been approved for advanced liposarcoma (LPS).

Methods: In this study, we evaluated the effect of eribulin on proliferation, migration and invasion capabilities in LPS, leiomyosarcoma (LMS) and fibrosarcoma (FS) models, using both monolayer (2D) and three-dimensional (3D) spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the treatment of STS with the aim of increasing its antitumour activity.

Results: Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line models. Furthermore, we provide data that suggest, for the first time, a synergistic effect with ifosfamide in all models, and with pazopanib in LMS as well as in myxoid and pleomorphic LPS.

Conclusions: Our results support the effect of eribulin on LPS, LMS and FS cell line models. The combination of eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.

CITATION  Cancer Cell Int. 2021 Dec 4;21(1):646.  doi: 10.1186/s12935-021-02337-5